Business Context and Reporting Period
Company: Aardvark Therapeutics, Inc. (AARD)
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2025
Event: Presentation of clinical and preclinical data at the ObesityWeek 2025 conference and announcement of an investor webinar.
Key Financial Metrics
This filing is a current report regarding corporate events and scientific disclosures. It does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial metric.
Material Changes
No material financial changes are reported in this document. The material event is the dissemination of scientific data regarding the Company's obesity pipeline:
- ARD-101: A TAS2R agonist shown to attenuate weight gain in mice and reduce hunger in adults with obesity.
- WE-868: An isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes.
Guidance, Outlook, and Management Commentary
Management Commentary: The Company presented posters summarizing data for ARD-101 and WE-868. Management noted that the information is summary in nature and speaks as of the report date. The Company disclaims any obligation to update the posters in the future.
Outlook/Events: The Company announced an investor webinar scheduled for November 5, 2025, to review the ARD-101 and ARD-201 programs and the ObesityWeek 2025 presentations.
Risks and Contingencies: The filing includes standard disclaimers that the poster information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly provided.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.3) for detailed data points not summarized in the 8-K.
- Examine the attached posters (Exhibits 99.1 and 99.2) for specific clinical trial results and study limitations.
- Attend or review the recording of the investor webinar scheduled for November 5, 2025.
- Verify the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.